Immunology & inflammation · Live ClinicalTrials.gov data

Deucravacitinib (Sotyktu) clinical trial pipeline

The timeline below tracks the 16 largest phase 2–4 deucravacitinib (Sotyktu) trials on ClinicalTrials.gov by enrolment, 2 of them actively recruiting. The next phase 3 primary completion among them is expected Oct 2026. Refreshed daily. Add up to four competitors to compare pipelines side by side.

16+

Major trials tracked

9

Phase 3 trials

2

Actively recruiting

Oct 2026

Next phase 3 primary completion

8,931

Participants across trials

Bristol-Myers Squibb

Lead sponsor by trial count

deucravacitinib (16)9 active20162032
deucravacitinib
Key
Actual date
Anticipated
Forecast to primary completion
RecruitingActive, not recruitingNot yet recruitingCompletedTerminated
'16
'18
'20
'22
'24
'26
'28
'30
'32
deucravacitinib
Study to Evaluate Effectiveness and Safety in Subjects With Moderate to Severe PsoriasisP2
An Investigational Study to Evaluate BMS-986165 in Participants With Systemic Lupus ErythematosusP2
An Investigational Study of Experimental Medication BMS-986165 in Participants With Moderate to Severe Crohn's DiseaseP2
POETYK-PSO-1P3
Long-Term Safety and Efficacy Study of Deucravacitinib in Participants With Systemic Lupus ErythematosusP2
An Investigational Study to Evaluate Experimental Medication BMS-986165 in Japanese Participants With Moderate-to-Severe PsoriasisP3
POETYK PSO-LTEP3
POETYK-PSO-3P3
A Study to Evaluate the Drug Levels, Efficacy and Safety of Deucravacitinib in Children and Adolescent Participants With Moderate to Severe Plaque PsoriasisP3
A Study to Evaluate Efficacy and Safety of Deucravacitinib in Participants With Active Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE)P2
A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease-modifying Anti-rheumatic DrugsP3
POETYK SLE-1P3
IMMpactfulP4
Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)P3
COMBoP4
A Clinical Trial of TQH3906 Capsules in Adult Patients With Moderate to Severe Plaque PsoriasisP3

Upcoming readouts

5 ahead · deucravacitinib

Select a trial to load its full ClinicalTrials.gov record.

Key deucravacitinib trials

Top 12 of the 16 tracked phase 2–4 trials, ordered by phase and status. Trial names open the full ComplyRx trial page; NCT ids link to ClinicalTrials.gov.

TrialTitlePhaseStatusPrimary completion
NCT07280702COMBo: Deucravacitinib-TNFi Combination Therapy for Difficult-to-Control Psoriatic DiseasePhase 4Not yet recruitingDec 2027
NCT06333860IMMpactful: A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Trea…Phase 4CompletedMar 2026
NCT04772079A Study to Evaluate the Drug Levels, Efficacy and Safety of Deucravacitinib in Children and Adol…Phase 3RecruitingJan 2029
NCT07116967Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRA…Phase 3RecruitingJan 2031
NCT04908202A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Partici…Phase 3Active, not recruitingSept 2024
NCT04036435POETYK PSO-LTE: Long-Term Study That Measures the Safety and Efficacy of Deucravacitinib (BMS-986165) in Partici…Phase 3Active, not recruitingJul 2026
NCT05617677POETYK SLE-1: A Study to Assess Effectiveness and Safety of Deucravacitinib Compared With Placebo in Participa…Phase 3Active, not recruitingOct 2026
NCT07724366A Clinical Trial of TQH3906 Capsules in Adult Patients With Moderate to Severe Plaque PsoriasisPhase 3Not yet recruitingSept 2027
NCT03624127POETYK-PSO-1: Effectiveness and Safety of BMS-986165 Compared to Placebo and Active Comparator in Participants…Phase 3CompletedSept 2020
NCT04167462POETYK-PSO-3: An Investigational Study to Evaluate Experimental Medication BMS-986165 Compared to Placebo in P…Phase 3CompletedMar 2021
NCT03924427An Investigational Study to Evaluate Experimental Medication BMS-986165 in Japanese Participants…Phase 3CompletedMar 2021
NCT04857034A Study to Evaluate Efficacy and Safety of Deucravacitinib in Participants With Active Discoid a…Phase 2Active, not recruitingAug 2024

Track deucravacitinib with ComplyRx

Get an alert when a trial changes status, moves its completion date, or a new trial registers in scope. Checked nightly against ClinicalTrials.gov.

Track deucravacitinib

FAQ

How many clinical trials are running for deucravacitinib?
ClinicalTrials.gov lists more than 16 phase 2–4 deucravacitinib trials. This page tracks the 16 largest by enrolment: 5 phase 2, 9 phase 3, and 2 phase 4 among them, with 2 actively recruiting. Updated daily.
Are there clinical trials for Sotyktu?
Sotyktu is the brand name for deucravacitinib, so deucravacitinib trials on ClinicalTrials.gov cover it. ClinicalTrials.gov lists more than 16 phase 2–4 deucravacitinib trials. This page tracks the 16 largest by enrolment: 5 phase 2, 9 phase 3, and 2 phase 4 among them, with 2 actively recruiting. Updated daily.
Where does this data come from?
All trial data is sourced from ClinicalTrials.gov (CTGov) and refreshed on this page daily.
Can I compare deucravacitinib against other drugs?
Yes. The free ComplyRx Trial Pipeline tool compares up to five drugs side by side on one timeline, with PNG and PDF export. Add any competitor in the search box above.
Join the waitlist

Be the first to access ComplyRx

We'll let you know as soon as your spot opens to use ComplyRx.

By joining, you agree to our Privacy Policy.